Form 4 Filing for Replimune Group, Inc. (REPL)

This Form 4 filing reports transactions made by Christopher Sarchi, Chief Commercial Officer of Replimune Group, Inc. On April 1, 2026, Sarchi acquired 50,000 shares of Common Stock and was granted an Employee Stock Option to purchase 75,000 shares of Common Stock. The acquisition of Common Stock is related to restricted stock units (RSUs) granted to Sarchi, which vest in stages through May 15, 2030. The stock option, with an exercise price of $7.61, has 25% of its underlying shares vesting on April 1, 2027, with the remainder vesting in monthly installments over the following three years. The filing was submitted late due to an administrative error.